Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Rybelsus is an oral form of semaglutide, the active ingredient in the company’s blockbuster Ozempic and Wegovy diabetes and weight-loss drugs, and was tested in the trial on diabetic patients ...

The survey of 1,078 adults, carried out by Ipsos, found 24% of people would use weight-loss jabs if they were provided for ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

However, while Wegovy is prescribed by the NHS for weight management, Rybelsus is not licensed for such and is only available as a treatment for Type 2 diabetes. There are other limitations too. In ...

Rybelsus, a daily pill approved in 2019 for Type 2 diabetes, contains the same active ingredient as Ozempic and Wegovy. The study enrolled 9,650 Type 2 diabetes patients who have cardiovascular ...

However, what sets Rybelsus apart from its sibling treatments is that it is an oral pill, whereas Ozempic and Wegovy are administered via injection. For much of 2024, Novo Nordisk has been ...

Novo Nordisk plans to seek regulatory approval for Rybelsus label expansion by late 2024 or early 2025. On Monday, Novo Nordisk A/S NVO released the headline results from the SOUL Phase 3 ...

Novo Nordisk’s diabetes pill Rybelsus cut the risk of heart attacks, strokes and cardiovascular death by 14% in a Phase 3 trial of people with diabetes and established heart or kidney disease ...